SAGE Therapeutics Inc (OQ:SAGE)

Business Focus: Biotechnology & Medical Research

INK Ultra Money Free

Latest 10 SEC filings (by transaction date) for SAGE within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET April 9th, 2020
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
Feb 14/20 Feb 12/20 Kanes Stephen Direct Ownership Stock Option (Right to Buy) A - Grant, award or other under Rule 16b-3(d) 17,500  
Feb 14/20 Feb 12/20 Iguchi Kimi Direct Ownership Stock Option (Right to Buy) A - Grant, award or other under Rule 16b-3(d) 17,500  
Feb 14/20 Feb 12/20 Robichaud Albert Direct Ownership Stock Option (Right to Buy) A - Grant, award or other under Rule 16b-3(d) 20,000  
Feb 14/20 Feb 12/20 Cook Anne Marie Direct Ownership Stock Option (Right to Buy) A - Grant, award or other under Rule 16b-3(d) 20,000  
Feb 14/20 Feb 12/20 Cloonan Michael Direct Ownership Stock Option (Right to Buy) A - Grant, award or other under Rule 16b-3(d) 22,500  
Feb 14/20 Feb 12/20 Jonas Jeffrey M Direct Ownership Stock Option (Right to Buy) A - Grant, award or other under Rule 16b-3(d) 50,000  
Jan 7/20 Jan 3/20 Golumbeski George Direct Ownership Stock Options (Right to buy) A - Grant, award or other under Rule 16b-3(d) 976  
Dec 10/19 Dec 10/19 Iguchi Kimi Direct Ownership Stock Option (Right to Buy) M - Exercise or conversion exempt under rule 16b-3 -500  
Dec 10/19 Dec 10/19 Iguchi Kimi Direct Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 500 $1.36
Dec 10/19 Dec 9/19 Iguchi Kimi Direct Ownership Stock Option (Right to Buy) M - Exercise or conversion exempt under rule 16b-3 -15,000  
Sign up or login above to see all SEC filings within the past 6 months.
Latest 10 SEC filings (by filing date) for SAGE within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:59pm ET April 9th, 2020
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction Volume or Value Price
Feb 14/20 Feb 12/20 Kanes Stephen Direct Ownership Stock Option (Right to Buy) A - Grant, award or other under Rule 16b-3(d) 17,500  
Feb 14/20 Feb 12/20 Iguchi Kimi Direct Ownership Stock Option (Right to Buy) A - Grant, award or other under Rule 16b-3(d) 17,500  
Feb 14/20 Feb 12/20 Robichaud Albert Direct Ownership Stock Option (Right to Buy) A - Grant, award or other under Rule 16b-3(d) 20,000  
Feb 14/20 Feb 12/20 Cook Anne Marie Direct Ownership Stock Option (Right to Buy) A - Grant, award or other under Rule 16b-3(d) 20,000  
Feb 14/20 Feb 12/20 Cloonan Michael Direct Ownership Stock Option (Right to Buy) A - Grant, award or other under Rule 16b-3(d) 22,500  
Feb 14/20 Feb 12/20 Jonas Jeffrey M Direct Ownership Stock Option (Right to Buy) A - Grant, award or other under Rule 16b-3(d) 50,000  
Feb 4/20 Aug 29/19 Frates James M Direct Ownership Common Stock Form 5 : Annual Statement of Beneficial Ownership of Securities -1,500  
Jan 7/20 Jan 3/20 Golumbeski George Direct Ownership Stock Options (Right to buy) A - Grant, award or other under Rule 16b-3(d) 976  
Dec 10/19 Dec 10/19 Iguchi Kimi Direct Ownership Stock Option (Right to Buy) M - Exercise or conversion exempt under rule 16b-3 -500  
Dec 10/19 Dec 9/19 Iguchi Kimi Direct Ownership Stock Option (Right to Buy) M - Exercise or conversion exempt under rule 16b-3 -15,000  
Sign up or login above to see all SEC filings within the past 6 months.
Sign up or login above to see the past 6 months of filings sorted by insider. .
Get holdings trends & enhanced insider charts in PDF now

Twitter

Search (past week) for $SAGE

Competitors

Competitors with Recent Insider Filings
Iqvia Holdings (N:IQV)
Alnylam Pharmaceuticals (OQ:ALNY)
Vir Biotechnology (OQ:VIR)